Kornimate/medical-research-clean huggingface dataset:
vitamin d levels in children with bacterial meningitis

Conditions: Bacterial Meningitis

Summary: the purpose of this study is to determine whether deficiency of vitamin d has association with outcomes of children with bacterial meningitis.

vitamin d deficiency has been proved in serious diseases patients, including patients in shock, however, few study have been done about association between deficiency of vitamin d and outcomes of children with bacterial meningitis. in our study, we will observe incidence of complication and severity of complication between patients who have different vitamin d status.

Eligibility criteria:
inclusion criteria: * probable bacterial meningitis patients: clinical manifestation (any person with sudden onset of fever (\> 38.5 °c rectal or 38.0 °c axillary) and one of the following signs: neck stiffness, altered consciousness or other meningeal sign) with cerebrospinal fluid examination showing at least one of the following: a. turbid appearance; b.leukocytosis (\> 100 cells/mm3); c.leukocytosis (10-100 cells/ mm3) and either an elevated protein (\> 100 mg/dl) or decreased glucose (\< 40 mg/dl) * confirmed bacterial meningitis patients: a case that is laboratory-confirmed by growing (i.e. culturing) or identifying (i.e. by gram stain or antigen detection methods) a bacterial pathogen (hib, pneumococcus or meningococcus) in the cerebrospinal fluid or from the blood in a child with a clinical syndrome consistent with bacterial meningitis exclusion criteria: * congenital immunodeficiency patients * hiv patients * patients with corticosteroid treatment for long time * patients with disorders in adrenal gland and pituitary gland and hypothalamus * patients with tuberculosis
occipital nerve stimulation for the treatment of chronic migraine headache.

Conditions: Chronic Migraine Headache

Summary: background: medically intractable chronic migraine (cm) is a disabling illness characterized by headache greater than 15 days per month. method: a multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ons) in cm. eligible subjects received an occipital nerve block, and responsers were randomized to adjustable stimulation (as), preset stimulation (ps) or medical management (mm) groups.

the therapy under investigation involves a medtronic neurostimulation device which delivers electrical impulses via insulated lead wires placed under the skin near the occipital nerves at the base of the head.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic migraine headache by international headache society (ihs) criteria * compliance with daily questionnaire * headache that has not responded to at least two classes of headache medications * stable headache medication regimen exclusion criteria: * previous surgical procedures to disrupt the nerves of the neck relating to the headache * subjects who may require mri or diathermy
cardiovascular risk factors in a cohort of latina women

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to conduct a cross-sectional study of cardiovascular risk factors in a cohort of latina women.

background: cardiovascular disease (cvd) is the leading cause of death among latina women (lw) in the united states. nursing knowledge in the area of cvd and latina women is currently underdeveloped. most studies have included mexican women with limited information on how predictors such as resources, situational, personal, and demographic factors have an effect on the cvd-related dietary practices, physical activity, and exercise practices among latina women subgroups such as central american women. design narrative: to conduct a cross-sectional and follow-up preliminary intervention study in order to describe and analyze the cvd-related diet, physical activity, and exercise practices predictors in 221 mexican and central american women recruited from six counties in northern california. face-to-face interviews were conducted with mexican american and central american women (ages 40-75) who had at least one risk factor for cvd to answer the following questions: what were the cvd-related risk factors, dietary practices, physical activity, and exercise behaviors in mexican and central american women who were 40 to 75 years and who had at least one risk factor for cvd? what was the relationship between predictor variables (resources, situational, personal, and demographic factors) with cvd-related diet practices, physical activity, and exercise behaviors (outcome variables)?, and what were the short and intermediate-term effects of a cardiovascular nursing intervention on diet, physical activity, and exercise? a sample of 221 women was targeted. data were collected during the first two years of the project to provide substantial research-based information to develop a cardiovascular nursing intervention to support latina women efforts to promote heart health and prevent cvd. data were analyzed during the third year and the cardiovascular nursing intervention was developed to determine the short (3 months) and intermediate-term (6 months) effects in the outcome variables. a randomly selected sample of 60 women from the same cohort was randomly assigned to the developed intervention group (n=30 in each group) and to a delayed-intervention control group. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
the comparison of educational effectiveness between fast and stroke 112 in yunlin community

Conditions: Stroke, Cardiovascular

Summary: fast and stroke-112 are two campaigns to reduce the emergency room arrival time of stroke patients. no study has evaluated the effectiveness of these campaigns. this study aimed to compare recalling capacity of people in these two campaigns.

cerebral vascular accidents have been one of the leading causes of death in taiwan in recent years. in the modern medical system, treatment for hyperacute stroke including intravenous thrombolysis and intra-arterial thrombectomy. the faster patient received treatment, the better outcome he has. prehospital delay of acute stroke treatment has been an important issue in modern medical system. awareness of stroke symptoms and calling for medical help immediately is the most important part of stroke health education. the most used educational campaign is fast. in recent years, there is another stroke educational campaign called stroke 112. previous study had showed it has greater acceptance, since the number is easier to remember then letter, especially in non-english speaking countries. the investigators had conducted a hospital-based randomized study in 2019, which revealed that stroke 112 had similar, but not superior effectiveness with fast. however, more study is needed for community-based population. this study will compare and explore the effectiveness of two stroke educational campaigns, fast and stroke 112, on community-based population by using the questionnaire, in yunlin, taiwan. the result will been compared and analyzed with previous study, help us modify and enhance our current stroke educational program, shorten the prehospital delay, and improve outcomes of patients with acute stroke. the subjects will be randomized into either group: fast or stroke 112. then the investigator will give a 15min eduacation. the evaluation will be arranged 5 days and 30 days after the first education, and the outcome is the recalling capacity of the stroke symptoms in the educational campaign.

Eligibility criteria:
inclusion criteria: * age ≥ 20 * individuals who could speak either mandarin or taiwanese as their mother tongue exclusion criteria: * individuals who could not understanding the education campaign(ex. dementia, aphasia) * individuals who were previously aware about either campaign
safety and performance evaluation of tulip device in healthy overweight and obese volunteers

Conditions: Over Weight; Obesity

Summary: the study will assess the safety and performance of an intragastric auto-inflating and degradable balloon

the study will assess the safety and performance of an intragastric auto-inflating and degradable balloon, packed in a swallow-able capsule, in healthy subjects with 30 \< bmi≤ 35.

Eligibility criteria:
inclusion criteria: * 21 ≤ age \<65 years * 30 \< bmi ≤ 35 kg/m2 * healthy without any medication; * no history of weight reduction of more than 5% of total body weight in the past 6 months; * normal blood count and chemistry; * hemoglobin level over 11; * at least 3 bowel movements per week; * subject declares that he/she is able to go through gastroscopic examination; * subject is able and willing to give informed consent and follow protocol procedures. exclusion criteria: * any history or evidence of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results; * history or evidence of any active liver disease. (abnormal liver functions: \>1.5 times upper limit); * history or symptoms of thyroid disease which is not controlled by medication; * abnormal gastrointestinal findings: diaphragmatic hernia \> 3 cm; active peptic ulcer; erosive gastritis; gastric outlet obstruction; * subject with ibd * significant swallowing disorders; * past history of any gastrointestinal surgery (excluding uncomplicated appendectomy); * malabsorption disorders. * is taking medications that reduce gastric acidity * currently using pharmaceutical agents or food supplements for weight loss; * history of or current eating disorder such as anorexia or bulimia or compulsory overeating. * history of food allergy; * subject with poor venous access; * is taking chronic aspirin or other non-steroidal anti-inflammatory agents, or other medications known to be gastric irritants; * have any coagulation problem and/or taking any anticoagulant medications; * evidence of current malignant disease; * have history of any acute disease (viral, bacterial, pain, accident) in the last 6 weeks. * female subject who are breastfeeding or have a positive pregnancy test at screening or at any time during the study; * inability to give written informed consent; * history of alcohol or drug abuse within 6 months of screening; * mental disorders; * currently participating in an ongoing clinical study * any reasons making the patient a poor candidate in the opinion of the investigator.

Keywords: over weight obesity
no stoma vs ghost stoma in patients undergoing total mesorectal excision for rectal cancer

Conditions: Rectal Neoplasms

Summary: this study aimed at comparing the comprehensive complication index (cci), readmission rates, postoperative hospitalization days, duration of bearing the stoma (months), hospitalization costs, the number of hospitalizations with ghost ileostomy group versus no ileostomy group after total mesorectal excision for rectal cancer.

so far, there are no relevant reports on ghost ileostomy among the asian population, and all studies are small sample studies.in the past decades, with the advent of circular stapling devices, many middle and low rectal cancers have chosen new sphincter-saving procedures (such as isr and ta tme). nevertheless, when the incidence rate of al remains high, is diverting ileostomy applicable? is ghost ileostomy applicable to rectal cancer in the context of new surgical procedures such as pelvic floor reconstruction, perineal drainage, anastomotic reinforcement and robotic surgery? is this delayed stoma safe and feasible with the increase of preoperative neoadjuvant therapy? therefore, our study proposes to summarize the review of the complications of gi and no stoma to explore the safety and effectiveness of gi in clinical practice.

Eligibility criteria:
inclusion criteria: * pathologically confirmed rectal cancer. * age ≥18 years and ≤80 years. * intraoperative ghost ileostomy or no stoma was performed. exclusion criteria: * asa score \>3. * patients with coexisting complete intestinal obstruction. * history of long-term use of immunosuppressive drugs or glucocorticoids. * combined severe cardiac disease: with congestive heart failure or nyha cardiac function ≥ grade 2. * patients with a history of myocardial infarction or coronary artery surgery within 6 months before the procedure. * chronic renal failure (requiring dialysis or glomerular filtration rate \<30 ml/min). intraoperative combined multi-organ resection. * combined cirrhosis of the liver. * intraoperative findings of incomplete anastomosis and positive insufflation test.

Keywords: ghost ileostomy no ileostomy rectal cancer
regulatory b cells and chronic immune thrombocytopenia

Conditions: Purpura, Thrombocytopenic, Idiopathic; Regulatory B Cells

Summary: the chronic immune thrombopenia is an autoimmune disease caused by b cells. these cells produce anti platelets and megakaryocytes antibodies. some b cells, named regulatory b cells, are known to control other cells. their action in chronic immune thrombopenia is actually unknown.

the chronic immune thrombopenia is an autoimmune disease caused by b cells. these cells produce anti platelets and megakaryocytes antibodies. some b cells, named regulatory b cells, are known to control other cells. their action in chronic immune thrombopenia is actually unknown. in our cohort of chronic immune thrombopenia and controls, we realized a flow cytometry analyze of b and t cells and a co-culture to determine regulatory b cells functionality.

Eligibility criteria:
inclusion criteria: * purpura, thrombocytopenic, idiopathic, chronic phase (\>12 months) * no treatment or thrombopoietin receptor agonists exclusion criteria: * \< 18 years * purpura, thrombocytopenic, idiopathic, acute phase * pregnancy * others causes of thrombopenia
a study of aspirin and clopidogrel in patients with idiopathic pulmonary arterial hypertension

Conditions: Hypertension, Pulmonary

Summary: rationale: idiopathic pulmonary arterial hypertension (ipah) is characterized by in situ thrombosis and increased thromboxane a2 (tx-m) synthesis. while both may be attributable to abnormal platelet function, there are no studies of anti-platelet therapy in ipah. objectives: the purpose of this study is to assess the effects of aspirin (asa) and clopidogrel on platelet function and eicosanoid metabolism in patients with ipah.

this is a randomized, double-blind, placebo-controlled crossover study of aspirin 81 mg once daily and clopidogrel 75 mg once daily. platelet function is assessed with plasma p-selectin levels and aggregometry after exposure to adenosine diphosphate, arachidonic acid, and collagen. we will assess serum levels of thromboxane b2 and urinary metabolites of thromboxane a2 and prostaglandin i2 (tx-m and pgi-m, respectively).

Eligibility criteria:
inclusion criteria: * diagnosis of ipah * ≥ 18 years of age * nyha functional class i, ii, or iii * clinical stability (i.e., without change in pulmonary arterial hypertension medical regimen within one month prior to enrollment). exclusion criteria: * other forms of pah * a contraindication to asa or clopidogrel * thrombocytopenia (defined as platelet count ≤ 75,000) * history of intracranial hemorrhage or chronic thromboembolic disease * renal failure * inability or unwillingness to avoid non-steroidal anti-inflammatory agents, asa, or warfarin use for the duration of the trial

Keywords: platelets
immunogenicity and safety study of a three-dose biothrax® regimen for post-exposure prophylaxis in healthy adults

Conditions: Anthrax

Summary: the purpose of this phase 3 clinical trial is to evaluate the immunogenicity and safety of biothrax anthrax vaccine in healthy adults following 3 doses of biothrax. results of this study will be used to support a post-exposure prophylaxis (pep) indication for biothrax. this study will be conducted in the united states (u.s.), in 200 healthy male and female volunteer subjects ages 18 to 65 years. the duration of study participation for each individual subject will be approximately 128 days (4.25 months), including a screening period of approximately 28 days followed by 100 days on study.

biothrax® (also called anthrax vaccine adsorbed or ava) is the only fda-licensed vaccine for the prevention of anthrax infection. this study will evaluate the immunogenicity of the vaccine using a post-exposure vaccination schedule. correlations will be drawn to immunogenicity and survival data from animal models to demonstrate that biothrax® can elicit a protective immune response for pep.

Eligibility criteria:
inclusion criteria: * be between 18 and 65 years of age, inclusive, at the time of enrollment. * be in good health as determined by the investigator from medical history and a physical examination. * if a pre-menopausal female, must be using acceptable methods of birth control. * have all hematology and chemistry parameters (measured at screening) within the laboratory's normal range. * be willing and able to return for all visits and blood collections for the duration of the study. * have read, understood and signed an informed consent form. exclusion criteria: * prior immunization with anthrax vaccine or known exposure to anthrax organisms. * intend to enlist in the military during the study. * have a known allergy to aluminum hydroxide, formaldehyde, benzethonium chloride, or latex. * plan to receive experimental products at any time during the study. * have received a live vaccine in the 30 days before study entry. * plan to receive a live vaccine at any time during the study. * have ongoing drug abuse/dependence (including alcohol) issues and/or test positive in a urine drug screen for amphetamines, barbiturates, cocaine or opiates; * have received immunosuppressive therapy (including systemic steroids) within 3 months prior to study entry. * have a condition known to produce or be associated with immunosuppression. * have received cytotoxic therapy in the previous 5 years. * a medical condition that, in the opinion of the principal investigator (pi), could adversely impact the subject's participation, safety, or conduct of the study.

Keywords: post-exposure prophylaxis toxin neutralization assay
brain, gut and kidney blood flow during medical closure of pda

Conditions: Patent Ductus Arteriosus

Summary: the purpose of this study is to determine how the medications which are used to close the patent ductus arteriosus (pda) in preterm infants affect brain, kidney and gut blood flow when compared to infants that are not treated with these medications. the medications being used for pda closure are indomethacin and neoprofen.

all babies requiring medical treatment of their pda will receive up to 3 doses of medication. for babies enrolled in the control group of this study, she/he will not be treated with either of these medicines.

Eligibility criteria:
inclusion criteria: * less than or equal to 32 weeks gestation; * less than or equal to 1250 g; * mechanical ventilation; * echocardiographic findings of pda with left to right shunting; * medical judgement of neonatologist for medical treatment; exclusion criteria: * urine output less than 1 ml/k/hr over previous 12 hours; * serum creatinine greater than 1.5 mg/dl; * platelet count less than 100,000 per cubic mm; * significant skin breakdown at sensor areas; * significant congenital anomalies * intraventricular hemorrhage greater than or equal to grade iii

Keywords: patent ductus arteriosus indomethacin neoprofen blood flow
secondary prevention and health promotion after stroke

Conditions: Stroke

Summary: the aim of this study was to examine to what extent a one year population of stroke patients at a university hospital had well regulated risk factors and health problems one year after stroke, and if a structured nurse-led previous follow-up in the intervention group including referrals if needed could influence health outcome and risk factors one year after stroke.

the follow-up protocol was categorized into risk factors, patients' self-reports, and other health problems. referral was sent to a physician if medical interventions were needed regarding risk factors measured above the limits as stated in the follow-up protocol in accordance with guidelines,and/or if any self-reported health problems were stated by the patients, or had been detected by the specialist nurse. primary outcome was comparison between the intervention group and control group at one year after stroke regarding proportion of regulated risk factors, and self-reports on health outcome. results of the two follow-ups of the intervention group were also compared.

Eligibility criteria:
inclusion criteria: who criteria for definition of stroke signed consent exclusion criteria: other diagnosis causing neurological symptoms

Keywords: complication depression follow-up intervention nurse-led outcome secondary prevention stroke
visual feedback monitoring during exercise in individuals with obesity

Conditions: Obesity

Summary: exercise has been shown to offer numerous health benefits and be particularly important in preventing weight gain or regain for people with obesity. exercise guidelines can be difficult to interpret and apply independently and do not address specific exercise limitations in individuals with obesity. the exercise monitoring system proposed in this study might provide a new method to meet aerobic exercise guidelines independently with reduced risk of injury. the exercise monitoring system controls, in real-time, the intensity of an exercise session consisting of treadmill walking. during treadmill walking, the exercise monitoring system will instruct participants to increase or decrease how much participants raise their knees and swing their arms while maintaining a smooth contact with the ground, based on real-time readings of the participants' heart rate. in this clinical trial, each participant will perform a control and an experimental training session. both training sessions will include four blocks of 7 minutes of treadmill walking alternated with three periods of rest (3 min). in the control session, participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting their walking speed. in the experimental session, each participant will follow the exercise monitoring system instructions displayed on a tv, and treadmill walking speed will be set at a comfortable walking speed. target heart rates of 60% hrr will be used as the exercise intensities in both training sessions. the investigators will examine energy expenditure, heart rate, and kinematic measures under control and experimental conditions. the goals of this clinical trial are to determine the effect of exercising with the exercise monitoring system in individuals with obesity. the investigators hypothesized that the experimental session will result in higher total energy cost and efficiency than the control session; and in lower heart rate error, tibial positive peak accelerations and feedback errors than the control session. the results of this study will inform proposals for larger interventions that will focus on 1) testing different types of obesity and osteoarthritis, 2) adding a resistance-training component, and 3) integrating a diet intervention.


Eligibility criteria:
inclusion criteria: * bmi ≥ 30.0 kg/m2 and ≤ 40.0 kg/m2 * age 20 to 45 years; * able to understand spoken english at the level needed to: * understand and follow instructions for equipment setup, testing, and task performance * answer questions related to effort and preference * be able to understand consent document and provide informed assent exclusion criteria: * any signs or symptoms suggestive of cardiovascular, pulmonary, metabolic, or renal disease. * any injury or health condition that affects the ability to walk on a treadmill.